The present invention provides a composition and a combined medication method for treating an enterovirus infection. In particular, the present invention provides a composition for inhibiting enteroviruses, wherein the composition at least contains an inhibitor of a 3D virus protein and an inhibitor of a capsid protein, or a combination of an inhibitor of a 3C protein and an inhibitor of a 3A protein.

The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.

The present invention provides a peptide that can be used to induce protective immunity to a norovirus belonging to a genotype of GII. A peptide comprising a portion of an amino acid sequence of a P domain of a VP1 protein of a norovirus, in which the norovirus belongs to any of genotypes of genogroup II (GII) (except genotype 4).

A Senecavirus A polypeptide generally includes at least a portion of 151-434 of SEQ ID NO:1, amino acids 435-673 of SEQ ID NO:1, or amino acids 674-937 of SEQ ID NO:1. The Senecavirus A polypeptide may be used as a capture antigen in a method or device for detecting antibody that specifically binds to the Senecavirus A polypeptide. The Senecavirus A polypeptide may be used as a immunogen to vaccinate a subject having or at risk of having a Senecavirus A infection.

Disclosed is an anti-norovirus antibody that reacts with noroviruses of many genotypes and can collectively detect the noroviruses. The anti-norovirus antibody or an antigen-binding fragment thereof undergoes antigen-antibody reaction with the peptides composed of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The anti-norovirus antibody, which can broadly bind to noroviruses and detect a wide range of human noroviruses with high specificity and sensitivity, and a norovirus immunoassay and a norovirus immunoassay device, both using the anti-norovirus antibody, are provided.

The present invention provides a composition and a combined medication method for treating an enterovirus infection. In particular, the present invention provides a composition for inhibiting enteroviruses, wherein the composition at least contains an inhibitor of a 3D virus protein and an inhibitor of a capsid protein, or a combination of an inhibitor of a 3C protein and an inhibitor of a 3A protein.

Disclosed are a method of testing a fecal sample, which method suppresses the effect of interfering substances contained in the fecal sample in immunochromatography, to enable accurate and specific measurement of a substance to be detected in the test sample, and an immunochromatographic test piece therefor. The method of testing a fecal sample includes testing the fecal sample by immunochromatography in the presence of a water-soluble polymer. The water-soluble polymer is, for example, a compound containing a polyoxyethylene moiety, or a polyacrylic acid or a salt thereof. The immunochromatographic test piece for testing a fecal sample includes the water-soluble polymer in a sample drop region.

Disclosed are a method of testing a fecal sample, which method suppresses the effect of interfering substances contained in the fecal sample in immunochromatography, to enable accurate and specific measurement of a substance to be detected in the test sample, and an immunochromatographic test piece therefor. The method of testing a fecal sample includes testing the fecal sample by immunochromatography in the presence of taurodeoxycholic acid or a salt thereof. The immunochromatographic test piece for testing a fecal sample includes taurodeoxycholic acid or a salt thereof in a sample drop region.

Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.

A Senecavirus A polypeptide generally includes at least a portion of 151-434 of SEQ ID NO:1, amino acids 435-673 of SEQ ID NO:1, or amino acids 674-937 of SEQ ID NO:1. The Senecavirus A polypeptide may be used as a capture antigen in a method or device for detecting antibody that specifically binds to the Senecavirus A polypeptide. The Senecavirus A polypeptide may be used as a immunogen to vaccinate a subject having or at risk of having a Senecavirus A infection.